PTC Therapeutics, Inc. (PTCT)

PTC Therapeutics, Inc. is trading at $72.72, down 0.23% on the session. The 50 day average sits at $77.37 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 41.4, which reads as weak, and MACD is bullish crossover. Volume is below average.

The nearest support is around $67.51 with resistance near $74.11, so that band frames the current range. Average daily movement is roughly $2.81, or about 3.9% of the share price, which is what any stop placement has to allow for. The overall health score of 43 out of 100 combines a trend score of 32, momentum of 49 and a risk score of 52.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.